23,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
12 °P sammeln
  • Broschiertes Buch

Adverse drug reactions (ADRs) are one of the important causes of morbidity and mortality. In order to minimize the harmful effects of medicines, countries have developed their own pharmacovigilance mechanisms. Yemen is a developing country in South West Asia with a National Pharmacovigilance Program (NPP). The current NPP in Yemen has limited coverage and receives only limited ADR reports. Though the program is successful to a certain extent, still there is a scope for improvement. This booklet discusses the drug regulation in Yemen, describing the existing limitations of these regulations,…mehr

Produktbeschreibung
Adverse drug reactions (ADRs) are one of the important causes of morbidity and mortality. In order to minimize the harmful effects of medicines, countries have developed their own pharmacovigilance mechanisms. Yemen is a developing country in South West Asia with a National Pharmacovigilance Program (NPP). The current NPP in Yemen has limited coverage and receives only limited ADR reports. Though the program is successful to a certain extent, still there is a scope for improvement. This booklet discusses the drug regulation in Yemen, describing the existing limitations of these regulations, demonstrating the need for pharmacovigilance and go throughout the different stages of pharmacovigilance activities in Yemen and finally how to foster pharmacovigilance activities to achieve the desired health care in Yemen. We hope that this booklet will serve as a useful reference for those individuals and organizations who are interested in Pharmacovigilance.
Autorenporträt
El Dr. Mohammed Alshakka completó su máster en Farmacia en la Universidad Ernst-Moritz-Arndt (Alemania) en 1987 y su doctorado en Farmacoepidemiología en la Universiti Sains Malaysia en 2013. Posteriormente, se incorporó a la Universidad de Adén (Yemen) como profesor adjunto en la Facultad de Farmacia. En 2014 fue nombrado director del Centro de Farmacovigilancia de Yemen.